State of Fragility Fractures Management during the COVID-19 Pandemic

Umberto Tarantino, Ida Cariati, Virginia Tancredi, Donato Casamassima, Eleonora Piccirilli, Riccardo Iundusi and Elena Gasbarra
Additional contact information
Umberto Tarantino: Department of Clinical Sciences and Translational Medicine, Faculty of Medicine and Surgery, “Tor Vergata” University of Rome, Via Montpellier 1, 00133 Rome, Italy
Ida Cariati: Department of Clinical Sciences and Translational Medicine, Faculty of Medicine and Surgery, “Tor Vergata” University of Rome, Via Montpellier 1, 00133 Rome, Italy
Virginia Tancredi: Department of System Medicine, Faculty of Medicine and Surgery, “Tor Vergata” University of Rome, Via Montpellier 1, 00133 Rome, Italy
Donato Casamassima: Department of Orthopaedics and Traumatology, “Policlinico Tor Vergata” Foundation, Viale Oxford 1, 00133 Rome, Italy
Eleonora Piccirilli: Department of Orthopaedics and Traumatology, “Policlinico Tor Vergata” Foundation, Viale Oxford 1, 00133 Rome, Italy
Riccardo Iundusi: Department of Orthopaedics and Traumatology, “Policlinico Tor Vergata” Foundation, Viale Oxford 1, 00133 Rome, Italy
Elena Gasbarra: Department of Orthopaedics and Traumatology, “Policlinico Tor Vergata” Foundation, Viale Oxford 1, 00133 Rome, Italy

IJERPH, 2020, vol. 17, issue 21, 1-7

Abstract: Osteoporosis is a public health concern all over the world. As a chronic condition, it generally requires prolonged medical interventions to limit the risks of further bone loss, impaired skeletal integrity and the onset of fractures. This problem is further complicated by the fact that the abrupt cessation of some therapies may be associated with an increased risk of harm. It is in this context that the COVID-19 pandemic has caused an unprecedented disruption to the provision of healthcare worldwide, exceeding our worst expectations in terms of the number of lives lost and the rapidity at which consolidated economies and healthcare systems are being significantly damaged. In this review, we assessed the challenges and strategies used in the management of osteoporosis and fragility fracture care during the COVID-19 pandemic. We also examined the available evidence and provided clinical recommendations that will require reassessment as the worldwide response to COVID-19 evolves.

Keywords: osteoporosis; COVID-19; fragility fractures; healthcare; aging; pulmonary infection; pandemic (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2020
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.mdpi.com/1660-4601/17/21/7732/pdf (application/pdf)
https://www.mdpi.com/1660-4601/17/21/7732/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:17:y:2020:i:21:p:7732-:d:433210

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().